← All organizations
B. Braun
For profitContributed to NME
Also known as: B BRAUN | BBraun Avitum Dialysis Center | B. Braun Korea Co., Ltd. | B. Braun Ltd. Centre of Excellence Infection Control | B BRAUN MEDICAL | B. Braun Medical Inc. | B BRAUN MEDICAL INC | B. Braun Medical International Trading Company Ltd. | B. Braun Medical LLC | B. Braun Medical SA | B. Braun Melsungen AG | B.Braun Taiwan Co., Ltd.
Highest phase reached
Phase 4
First clinical trial
Apr 1, 2003First marketed drug
Jan 17, 1946First NDA
Jan 17, 1946Last known activity
Nov 1, 2025
Timeline
1830s
- Jul 1, 1839
B. Braun— Founded
1980s
- Oct 3, 1980
sodium citrate— NDA Organization
2000s
- Mar 10, 2006
cefoxitin— NDA Secondary Org
2010s
- Apr 13, 2012
amino acids— Marketing Organization
Drugs by trial phase (34 distinct, 36 trials)
Phase 4 (24 own, 0 via acquisition)
Phase 3 (5 own, 0 via acquisition)
Phase 2 (5 own, 0 via acquisition)
Indications
Studied for
- Acute Lung Injury
- Angina Pectoris
- Angina, Stable
- Angina, Unstable
- Carcinoma
- Coronary Artery Disease
- Coronary Stenosis
- Critical Illness
- Cross Infection
- Diabetes Mellitus, Type 2
- Hyperlipidemias
- Hypovolemia
- Infarction
- Infections
- Ischemia
- Kidney Failure, Chronic
- Lung Injury
- Malnutrition
- Metabolic Syndrome
- Myocardial Infarction
- Neoplasm Metastasis
- Neoplasms, Second Primary
- Pancreatic Neoplasms
- Peritoneal Neoplasms
- Premature Birth
- Renal Insufficiency
- Respiratory Distress Syndrome
- Sepsis
- Shock
- Shock, Septic
- Staphylococcal Infections
- Stomach Neoplasms
- Toxemia
- Wounds and Injuries
Marketed drugs (57)
Recent trials (38)
- NCT07172451CollaboratorPhase 4Nov 1, 2025
- NCT05205486Lead sponsorPhase 1Apr 5, 2022
- NCT03967288CollaboratorPhase 4Aug 1, 2019
- NCT03618758CollaboratorPhase 1/Phase 2Jul 30, 2018
- NCT03338218Lead sponsorPhase 4May 1, 2018
- NCT03282955Lead sponsorPhase 4Jan 8, 2018
- NCT03231228Lead sponsorPhase 4Nov 20, 2017
- NCT03278548Lead sponsorPhase 4Sep 28, 2017
- NCT02808325Lead sponsorPhase 3Jun 1, 2016
- NCT02715466Lead sponsorPhase 4Apr 1, 2016
- NCT02601157CollaboratorPhase 4Dec 1, 2015
- NCT02609698CollaboratorPhase 4Aug 1, 2015
- NCT01904357Lead sponsorN/AMar 1, 2013
- NCT01814956Lead sponsorPhase 4Mar 1, 2013
- NCT01515397Lead sponsorPhase 3Dec 1, 2011
Details
- Founded
- Bethlehem, PA, US Jul 1, 1839
- First NDA
- Jan 17, 1946
- Last known activity
- Nov 1, 2025
Designations held
- Orphan drug
- Priority review